Core Viewpoint - Abbott's quarterly revenue fell short of Wall Street expectations due to weak performance in its diagnostics and nutrition segments, despite strong demand for its medical device products [1][2] Financial Performance - Abbott reported third-quarter revenue of approximately $11.37 billion, slightly below the average analyst expectation of $11.40 billion [1] - The company's adjusted earnings per share for Q3 were $1.30, in line with Wall Street's average forecast [2] - Abbott now expects full-year adjusted earnings per share to be in the range of $5.12 to $5.18, down from the previous range of $5.10 to $5.20, reflecting uncertainties from tariffs and regulatory policies [2] Business Segment Analysis - The diagnostics division, which includes sales of COVID-19 and diabetes testing products, saw an unexpected decline of 6.6% to $2.25 billion, below the average analyst expectation of $2.29 billion [1] - In contrast, the medical devices segment experienced a robust growth of 14.8%, reaching $5.45 billion, driven by strong demand for continuous glucose monitoring devices and advanced cardiac equipment [1] Industry Context - The healthcare sector is facing challenges from the normalization of demand post-COVID-19 and regulatory headwinds from the Trump administration's freeze on external economic aid [1] - Abbott's performance issues are attributed more to product mix and cyclical normalization rather than a collapse in demand [2]